Literature DB >> 20308373

Susceptibility of recently collected Spanish pneumococci nonsusceptible to oral penicillin from serotypes not included in the 7-valent conjugate vaccine.

Asunción Fenoll1, Lorenzo Aguilar, María-José Giménez, María-Dolores Vicioso, Olga Robledo, Juan-José Granizo, Pilar Coronel.   

Abstract

The susceptibilities of pneumococci recently collected (up to June 2009) in Spain (500 isolates nonsusceptible to oral penicillin and 150 susceptible isolates) from serotypes not included in the conjugate vaccine were determined. Most nonsusceptible isolates (53.6%) belonged to serotype 19A. Susceptibility rates in serotype 19A penicillin-intermediate (n = 201)/penicillin-resistant (n = 67) isolates were <33%/< or =6.0% (erythromycin and oral cephalosporins with defined breakpoints), 85.1%/11.9% (amoxicillin), and 96.0%/52.2% (cefotaxime), respectively. Low susceptibility to common oral beta-lactams was also found in serotypes 11A (95.5% susceptibility to cefotaxime and erythromycin) and 35B.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308373      PMCID: PMC2876354          DOI: 10.1128/AAC.01594-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal Vaccination for French children.

Authors:  Farah Mahjoub-Messai; Catherine Doit; Jean-Louis Koeck; Typhaine Billard; Bénédicte Evrard; Philippe Bidet; Christine Hubans; Josette Raymond; Corinne Levy; Robert Cohen; Edouard Bingen
Journal:  J Clin Microbiol       Date:  2008-12-24       Impact factor: 5.948

2.  Dot blot assay for the serotyping of pneumococci.

Authors:  A Fenoll; I Jado; D Vicioso; J Casal
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

3.  Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae.

Authors:  César García-Rey; Lorenzo Aguilar; Fernando Baquero; Julio Casal; Rafael Dal-Ré
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

4.  Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae?

Authors:  A Fenoll; L Aguilar; J J Granizo; M J Giménez; L Aragoneses-Fenoll; C Mendez; D Tarragó
Journal:  J Antimicrob Chemother       Date:  2008-09-26       Impact factor: 5.790

5.  Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-02-15       Impact factor: 17.586

6.  Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.

Authors:  Rosalyn J Singleton; Thomas W Hennessy; Lisa R Bulkow; Laura L Hammitt; Tammy Zulz; Debby A Hurlburt; Jay C Butler; Karen Rudolph; Alan Parkinson
Journal:  JAMA       Date:  2007-04-25       Impact factor: 56.272

7.  Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain.

Authors:  Carmen Ardanuy; Dora Rolo; Asunción Fenoll; David Tarrago; Laura Calatayud; Josefina Liñares
Journal:  J Antimicrob Chemother       Date:  2009-06-17       Impact factor: 5.790

8.  Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007.

Authors:  A Fenoll; J J Granizo; L Aguilar; M J Giménez; L Aragoneses-Fenoll; G Hanquet; J Casal; D Tarragó
Journal:  J Clin Microbiol       Date:  2009-02-18       Impact factor: 5.948

9.  Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007.

Authors:  Carmen Ardanuy; Fe Tubau; Román Pallares; Laura Calatayud; María Angeles Domínguez; Dora Rolo; Inmaculada Grau; Rogelio Martín; Josefina Liñares
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

10.  Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.

Authors:  Stephen I Pelton; Heather Huot; Jonathan A Finkelstein; C J Bishop; Katherine K Hsu; Joan Kellenberg; Susan S Huang; Richard Goldstein; William P Hanage
Journal:  Pediatr Infect Dis J       Date:  2007-06       Impact factor: 2.129

View more
  3 in total

1.  Update on the clinical utility and optimal use of cefditoren.

Authors:  José Barberán; Lorenzo Aguilar; María-José Giménez
Journal:  Int J Gen Med       Date:  2012-05-21

Review 2.  Cefditoren in upper and lower community-acquired respiratory tract infections.

Authors:  Francisco Soriano; María-José Giménez; Lorenzo Aguilar
Journal:  Drug Des Devel Ther       Date:  2011-02-09       Impact factor: 4.162

3.  Risk factors for death from invasive pneumococcal disease, Europe, 2010.

Authors:  Adoración Navarro-Torné; Joana Gomes Dias; Frantiska Hruba; Pier Luigi Lopalco; Lucia Pastore-Celentano; Andrew J Amato Gauci
Journal:  Emerg Infect Dis       Date:  2015-03       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.